Vaccine Maker Stocks Fall as Trump Chooses RFK Jr. to Lead HHS

The decision has sent shockwaves through the industry

Shares of major vaccine makers, including Pfizer, Moderna, and Johnson & Johnson, have plunged in recent days following the news that President Trump has appointed Robert F. Kennedy Jr. to head the Department of Health and Human Services (HHS).

Kennedy is a vocal critic of vaccines

Kennedy, the son of the late Senator Robert F. Kennedy, is a prominent anti-vaccine activist who has repeatedly linked vaccines to autism and other health problems. His appointment has raised concerns among public health experts, who fear that it could lead to a rollback of vaccine mandates and other policies that have helped to protect the public from preventable diseases.

In a statement, Pfizer said that it was "deeply concerned" by Kennedy's appointment. The company said that Kennedy's "anti-vaccine views are not based on science and have no place in public health policy." Moderna and Johnson & Johnson also expressed concerns about Kennedy's appointment.

The Trump administration has defended Kennedy's appointment, saying that he is a "highly qualified" individual who will bring a fresh perspective to HHS. However, the appointment has been met with widespread criticism from the medical community.

The American Academy of Pediatrics (AAP) said that it was "deeply disappointed" by Kennedy's appointment. The AAP said that Kennedy's "anti-vaccine views are not supported by science and are dangerous to public health."

The Infectious Diseases Society of America (IDSA) also expressed concern about Kennedy's appointment. The IDSA said that Kennedy's "anti-vaccine views are not based on science and could lead to a resurgence of vaccine-preventable diseases."

Kennedy's appointment is likely to have a significant impact on the vaccine industry. The industry is already facing challenges due to the declining demand for vaccines, and Kennedy's appointment could further erode public trust in vaccines.